黑龙江省双价肾综合征出血热疫苗免疫效果观察  

Observation on Immune Effects of Bivalent Vaccine of Hemorrhagic Fever with Renal Syndrome in Heilongjiang Province

作　　者：陈露菲[1] 陈淑红[1] 王开利[1] 刘彦成[1] 张静[1] 李冀宏[1] 

机构地区：[1]黑龙江省疾病预防控制中心,哈尔滨150030

出　　处：《中国公共卫生管理》2011年第1期64-65,共2页Chinese Journal of Public Health Management

基　　金：黑龙江省科技攻关计划项目(编号:GC06C424);黑龙江省卫生厅项目(2009-485)

摘　　要：目的分析黑龙江省大规模接种双价肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)疫苗免疫效果,为以疫苗接种为主的新防控对策在省内推广和应用提供科学依据。方法在黑龙江省出血热高发病地区的重点人群中实施浙江天元生物药业股份有限公司生产的双价HFRS疫苗接种,之后分析出血热疫情变化。结果全省2008年出血热发病数与2007年同期相比下降37.78%。27个市(县)区出血热疫苗接种点2008年出血热发病数与2007年同期相比下降40.81%。2008年1-9月发病数与2007年同期相比下降24.41%。2008年10-12月出血热发病数与2007年同期相比下降60.70%,接种疫苗者无一例发病。结论疫苗接种后出血热发病率下降幅度显著增加,事实证明在出血热高发病疫区采取疫苗接种是见效最快、最安全、效果最显著的防病措施。Objective To analyze the vaccine immune effectiveness of bivalent vaccine of hemorrhagic fever with renal syndrome（HFRS） in Heilongjiang Province,and to provide scientific basis for the new vaccine-based prevention strategy.Methods HFRS bivalent vaccine produced by Zhejiang Tianyuan Bio-pharmaceutical Company was inoculated in the susceptible people in high epidemic areas of Heilongjiang Province,and the surveillance data of HFRS was collected and analyzed.Results The case number declined 37.78% in 2008 comparing with that in 2007.In the vaccination areas of 27 counties,the case number declined 40.81% in 2008 comparing with that in 2007,and the case number declined 24.41% from January to September in 2008 comparing with the same period in 2007,but declined 60.70% from October to December.There was no patient among the vaccinated people.Conclusion The annual mean morbidity of HFRS declined obviously after vaccination,so the vaccine prevention strategy was fast,safe,effective measure for the disease prevention and control.

关 键 词：肾综合征出血热 疫苗 免疫效果 

分 类 号：R186[医药卫生—流行病学]